Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

Eurosurveillance

Volumn 23, Issue 31, 2018, Pages

  Galani, Irene ^a   Karaiskos, Ilias ^b   Karantani, Irene ^b   Papoutsaki, Vassiliki ^b   Maraki, Sofia ^c   Papaioannou, Vassiliki ^d   Kazila, Polyzo ^e   Tsorlini, Helen ^f   Charalampaki, Nikoletta ^g   Toutouza, Marina ^b   Vagiakou, Helen ^h   Pappas, Konstantinos ⁱ   Kyratsa, Anna ^j   Kontopoulou, Konstantina ^k   Legga, Olga ^l   Petinaki, Efthymia ^m   Papadogeorgaki, Helen ^b   Chinou, Efrosini ⁿ   Souli, Maria ^a   Giamarellou, Helen ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d KAT HOSPITAL   (Greece)

^e Theageneio Anticancer Hospital   (Greece)

^f G PAPANICOLAOU HOSPITAL   (Greece)

^g THRIASIO GENERAL HOSPITAL   (Greece)

^h G GENNIMATAS GENERAL HOSPITAL   (Greece)

ⁱ ATHENS NAVAL HOSPITAL   (Greece)

^j General Hospital of Corfu   (Greece)

^k Aristotle University of Thessaloniki   (Greece)

^l General Hospital of Lamia   (Greece)

^m UNIVERSITY HOSPITAL OF LARISSA   (Greece)

ⁿ SAINT SAVVAS HOSPITAL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CARBAPENEMASE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEMOCILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CLONAL VARIATION; EPSILOMETER TEST; ESCHERICHIA COLI; GENE IDENTIFICATION; GREECE; IN VITRO STUDY; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PULSED FIELD GEL ELECTROPHORESIS; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; GREECE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 85052405050     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2018.23.30.1700775     Document Type: Article

References (37)

1. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence. Euro Surveill. 2008;13(4):8023. https://doi. org/10.2807/ese.13.04.08023-en PMID: 18445397
2. Giakkoupi P, Papagiannitsis CC, Miriagou V, Pappa O, Polemis M, Tryfinopoulou K, et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J Antimicrob Chemother. 2011;66(7):1510-3. https://doi. org/10.1093/jac/dkr166 PMID: 21543359
3. Voulgari E, Gartzonika C, Vrioni G, Politi L, Priavali E, Levidiotou-Stefanou S, et al. The Balkan region: NDM-1-producing Klebsiella pneumoniae ST11 clonal strain causing outbreaks in Greece. J Antimicrob Chemother. 2014;69(8):2091-7. https://doi.org/}{\\}{ PMID: 24739146
4. Giakkoupi P, Tryfinopoulou K, Kontopidou F, Tsonou P, Golegou T, Souki H, et al. Emergence of NDM-producing Klebsiella pneumoniae in Greece. Diagn Microbiol Infect Dis. 2013;77(4):382-4. https://doi.org/10.1016/j. diagmicrobio.2013.09.001 PMID: 24135413
5. Spyropoulou A, Bartzavali C, Vamvakopoulou S, Marangos M, Anastassiou ED, Spiliopoulou I, et al. The first NDM metallo-β-lactamase producing Klebsiella pneumoniae isolate in a University Hospital of Southwestern Greece. J Chemother. 2016;28(4):350-1. https://doi.org/10.1179/197394781 5Y.0000000003 PMID: 25671611
6. Papagiannitsis CC, Malli E, Florou Z, Sarrou S, Hrabak J, Mantzarlis K, et al. Emergence of sequence type 11 Klebsiella pneumoniae coproducing NDM-1 and VIM-1 metallo-β-lactamases in a Greek hospital. Diagn Microbiol Infect Dis. 2017;87(3):295-7. https://doi.org/10.1016/j. diagmicrobio.2016.12.008 PMID: 27993422
7. Voulgari E, Zarkotou O, Ranellou K, Karageorgopoulos DE, Vrioni G, Mamali V, et al. Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11 clone. J Antimicrob Chemother. 2013;68(1):84-8. https://doi. org/}{\\}{ PMID: 22945916
8. Voulgari E, Poulou A, Dimitroulia E, Politi L, Ranellou K, Gennimata V, et al. Emergence of OXA-162 Carbapenemase-and DHA-1 AmpC Cephalosporinase-Producing Sequence Type 11 Klebsiella pneumoniae Causing Community-Onset Infection in Greece. Antimicrob Agents Chemother. 2016;60(3):1862-4. https://doi.org/}{\\}{ PMID: 26666930
9. Galani I, Anagnostoulis G, Chatzikonstantinou M, Petrikkos G, Souli M. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece. Clin Microbiol Infect. 2016;22(10):898-9. https://doi.org/}{\\}{ PMID: 27542333
10. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf
11. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351-70. https://doi.org/10.1517/14656566.2014.91 4172 PMID: 24766095
12. Adams-Haduch JM, Potoski BA, Sidjabat HE, Paterson DL, Doi Y. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2009;53(6):2700-1. https://doi.org/10.1128/AAC.00290-09 PMID: 19332667
13. Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470-84. https://doi.org/10.1080/2150559 4.2017.1292196 PMID: 28276996
14. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704-12. https://doi.org/10.1016/j.cmi.2017.09.001 PMID: 28893690
15. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0. Växjö: EUCAST; 2017. Available from: http://www.eucast.org
16. Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, et al. Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob Agents Chemother. 2009;53(9):4048-50. https://doi. org/10.1128/AAC.00690-09 PMID: 19581459
17. van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, Schouls LM. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS One. 2015;10(3):e0123690. https://doi.org/}{\\}{ PMID: 25798828
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. Växjö: EUCAST; 2016. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf
19. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints version 7.1. In European Committee on Antimicrobial Susceptibility Testing. Växjö: EUCAST; 2017. Available from: http://www.eucast.org
20. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988
21. Clinical and Laboratory Standards Institute (CLSI). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters. 4th ed. CLSI guideline M23. Wayne, PA: CLSI; 2016.
22. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8. https://doi.org/10.1016/S1473-3099(15)00424-7 PMID: 26603172
23. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surveill. 2016;21(27):30280. https://doi. org/10.2807/1560-7917.ES.2016.21.27.30280 PMID: 27416987
24. van Belkum A, Tassios PT, Dijkshoorn L, Haeggman S, Cookson B, Fry NK, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Epidemiological Markers (ESGEM). Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol Infect. 2007;13(Suppl 3):1-46. https://doi. org/10.1111/j.1469-0691.2007.01786.x PMID: 17716294
25. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11(2):159-77. https://doi. org/10.1586/eri.12.162 PMID: 23409822
26. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153-63. https://doi. org/10.1016/S1473-3099(16)30257-2 PMID: 27866944
27. Maltezou HC, Kontopidou F, Dedoukou X, Katerelos P, Gourgoulis GM, Tsonou P, et al. . Action Plan to combat infections due to carbapenem-resistant, Gram-negative pathogens in acute-care hospitals in Greece. J Glob Antimicrob Resist. 2014;2(1):11-6. https://doi.org/10.1016/j.jgar.2013.06.002 PMID: 27873631
28. Palacios-Baena ZR, Oteo J, Conejo C, Larrosa MN, Bou G, Fernández-Martínez M, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infect. 2016;72(2):152-60. https://doi.org/10.1016/j.jinf.2015.10.008 PMID: 26546855
29. Kaase M, Schimanski S, Schiller R, Beyreiß B, Thürmer A, Steinmann J, et al. Multicentre investigation of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in German hospitals. Int J Med Microbiol. 2016;306(6):415-20. https://doi.org/10.1016/j.ijmm.2016.05.009 PMID: 27237423
30. Huang TD, Bogaerts P, Berhin C, Hoebeke M, Bauraing C, Glupczynski Yon behalf of a multicentre study group. Increasing proportion of carbapenemase-producing Enterobacteriaceae and emergence of a MCR-1 producer through a multicentric study among hospital-based and private laboratories in Belgium from September to November 2015. Euro Surveill. 2017;22(19):30530. https://doi.org/10.2807/1560-7917.ES.2017.22.19.30530 PMID: 28537547
31. Dortet L, Cuzon G, Ponties V, Nordmann P. Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014. Euro Surveill. 2017;22(6):30461. https://doi.org/10.2807/1560-7917.ES.2017.22.6.30461 PMID: 28205502
32. Spyropoulou A, Papadimitriou-Olivgeris M, Bartzavali C, Vamvakopoulou S, Marangos M, Spiliopoulou I, et al. A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC-over VIM-or NDM-producing isolates. J Med Microbiol. 2016b;65(3):240-6. https://doi.org/10.1099/jmm.0.000217 PMID: 26698320
33. European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption. Surveillance and disease data. Antimicrobial consumption database. Trend by country. Stockholm: ECDC. [Accessed: November 2017]. Available from: http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-consumption/antimicrobial-consumption/esac-net-database/Pages/trend-consumption-by-country.aspx
34. Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect. 2007;13(5):541-4. https://doi.org/10.1111/j.1469-0691.2007.01708.x PMID: 17371537
35. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol. 2013;51(6):1678-84. https://doi.org/10.1128/JCM.03385-12 PMID: 23486719
36. Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269-85. https://doi.org/10.1016/j.ijantimicag.2016.02.001 PMID: 27013000
37. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862-72. https://doi.org/10.1111/1469-0691.12697 PMID: 24890393